
ACADIA Pharma (ACAD) Stock Forecast & Price Target
ACADIA Pharma (ACAD) Analyst Ratings
Bulls say
ACADIA Pharmaceuticals Inc. has demonstrated strong commercial execution and revenue growth, particularly with its pivotal products, NUPLAZID and DAYBUE, which are positioned to address significant unmet needs in neurological and rare diseases. The company projects combined net sales of approximately $1.7 billion by 2028, bolstered by robust year-over-year growth in DAYBUE, achieving $110 million in the latest quarter, exceeding consensus forecasts. Additionally, ongoing expansion of its field force and positive developments in intellectual property are expected to reinforce NUPLAZID revenue stability, supporting a positive trajectory for the company's financial outlook.
Bears say
ACADIA Pharmaceuticals faces significant challenges that contribute to a negative outlook on its stock, including the negative trend vote from the CHMP for trofinetide, which delays potential revenue from its EU launch and raises doubts about the product's market opportunity. Furthermore, key risks include uncertainties surrounding intellectual property, potential declines in reimbursement rates, and a slowing uptake of its core products, Nuplazid and Daybue, as well as existing safety concerns that could hamper market acceptance. Additionally, high dropout rates in clinical studies and mixed expert feedback regarding the efficacy of its therapies suggest that the company may struggle to demonstrate the meaningful benefits that would support robust market demand.
This aggregate rating is based on analysts' research of ACADIA Pharma and is not a guaranteed prediction by Public.com or investment advice.
ACADIA Pharma (ACAD) Analyst Forecast & Price Prediction
Start investing in ACADIA Pharma (ACAD)
Order type
Buy in
Order amount
Est. shares
0 shares